Avidity Biosciences, Inc.
RNA
$71.51
-$0.08-0.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 434.03% | 88.12% | -55.60% | 35.57% | -17.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 434.03% | 88.12% | -55.60% | 35.57% | -17.10% |
| Cost of Revenue | 100.72% | 116.02% | 48.87% | 81.05% | 61.79% |
| Gross Profit | -90.32% | -116.94% | -54.71% | -83.02% | -66.74% |
| SG&A Expenses | 99.08% | 77.82% | 141.76% | 75.80% | 69.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.34% | 106.67% | 64.86% | 79.82% | 63.52% |
| Operating Income | -92.40% | -107.13% | -70.39% | -81.28% | -67.39% |
| Income Before Tax | -116.97% | -122.22% | -68.14% | -69.18% | -53.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -116.97% | -122.22% | -68.14% | -69.18% | -53.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.97% | -122.22% | -68.14% | -69.18% | -53.55% |
| EBIT | -92.40% | -107.13% | -70.39% | -81.28% | -67.39% |
| EBITDA | -92.71% | -107.87% | -70.79% | -81.85% | -67.80% |
| EPS Basic | -94.11% | -83.30% | -13.48% | -0.13% | 7.77% |
| Normalized Basic EPS | -94.11% | -83.30% | -13.48% | -0.14% | 7.77% |
| EPS Diluted | -94.11% | -83.30% | -13.92% | -0.13% | 7.77% |
| Normalized Diluted EPS | -94.11% | -83.30% | -13.48% | -0.14% | 7.77% |
| Average Basic Shares Outstanding | 11.77% | 21.22% | 48.18% | 68.96% | 66.50% |
| Average Diluted Shares Outstanding | 11.77% | 21.22% | 48.18% | 68.96% | 66.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |